20-F: ImmunoPrecise Antibodies Reports Record Revenue Amidst AI Growth, Liquidity Concerns Persist

ImmunoPrecise Antibodies achieved record revenue and improved gross margins in fiscal year 2025, driven by its BioStrand AI segment, but continues to face significant net losses, liquidity challenges, and substantial intangible asset impairments.

Summary

• Revenue for the fiscal year ended April 30, 2025, was $24.5 million, flat compared to $24.5 million in fiscal year 2024, but up from $20.7 million in fiscal year 2023.
• Gross profit increased by 12.4% to $13.5 million in fiscal year 2025, up from $12.1 million in fiscal year 2024.
• Gross profit margin improved to 55.3% in fiscal year 2025, compared to 49.2% in fiscal year 2024, driven by higher revenue from the high-margin BioStrand segment and reduced salaries and lab supplies.
• Net loss for fiscal year 2025 increased to $30.2 million, compared to $26.1 million in fiscal year 2024, primarily due to a significant impairment of intangible assets.
• Total assets decreased to $44.4 million in fiscal year 2025 from $59.9 million in fiscal year 2024, while total liabilities decreased to $20.8 million from $24.3 million.
• Loss per share improved to ($0.91) in fiscal year 2025 from ($1.02) in fiscal year 2024.
• Cash on hand increased to $10.8 million as of April 30, 2025, from $3.5 million as of April 30, 2024.
• Cash used in operating activities was $6.4 million in fiscal year 2025, an increase from $3.2 million in fiscal year 2024.
• Research and development expenses increased by 22.3% to $4.9 million in fiscal year 2025, reflecting increased investment in the BioStrand segment.
• Sales and marketing expenses increased by 21.3% to $4.3 million in fiscal year 2025 due to marketing strategy and social media expenses.
• General and administrative expenses decreased by 5.5% to $14.7 million in fiscal year 2025 due to reductions in compensation and consulting expenses.
• An impairment loss of $21.2 million was recorded for intangible assets related to the BioStrand cash-generating unit in fiscal year 2025, primarily due to a delay in expected cash flows and an increased discount rate.
• The BioStrand segment's revenue grew over 180% in fiscal year 2025, now representing over 5% of total annual revenue, up from less than 2% in fiscal year 2024, with gross margins approaching 90%.
• The company regained compliance with Nasdaq's minimum bid price requirement on July 13, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While there are positives like record revenue, improved gross margins, and strong BioStrand growth, these are overshadowed by a significant increase in net loss due to large impairment charges, a substantial increase in cash burn from operations, and persistent liquidity concerns with the company explicitly stating it lacks sufficient cash for one year of operations. The material weakness in internal controls also adds to the negative sentiment.

Positives

• Achieved record-breaking revenue of $24.5 million in fiscal year 2025.
• Delivered the highest-ever fourth-quarter revenue of $7.0 million.
• Reported record fourth-quarter Adjusted EBITDA of ($0.3) million, reflecting improved operating efficiency.
• Achieved a fourth-quarter gross margin of 64%, representing the strongest margin performance since Q3 of fiscal year 2021.
• The BioStrand segment grew over 180% in fiscal year 2025 and had gross margins approaching 90%, indicating strong performance in its AI-driven initiatives.
• BioStrand now represents over 5% of total annual revenue, a significant increase from less than 2% in fiscal year 2024.
• Regained compliance with Nasdaq's minimum bid price requirement on July 13, 2025, resolving a potential delisting issue.
• Successfully completed the full conversion of the $3.0 million convertible debenture with Yorkville, enhancing the capital structure.

Negatives

• Incurred a net loss of $30.2 million in fiscal year 2025, an increase from $26.1 million in fiscal year 2024.
• Accumulated a deficit of $128.8 million as of April 30, 2025, and has incurred net losses since inception.
• Recorded a significant impairment loss of $21.2 million for intangible assets related to the BioStrand cash-generating unit in fiscal year 2025.
• Cash used in operating activities increased to $6.4 million in fiscal year 2025 from $3.2 million in fiscal year 2024.
• Does not have cash reserves to fund all operations for one year, indicating ongoing liquidity risk and a need for additional financing.
• Management concluded that a material weakness in internal controls over financial reporting existed as of April 30, 2025, due to insufficient resources for complex technical accounting issues, which remains unremediated.

Risks

• Negative operating cash flow and historical net losses, with no assurance of future profitability.
• Significant liquidity risk and potential need for additional capital, with no assurance of favorable financing terms or availability.
• Going concern risk due to insufficient cash reserves to fund operations for one year and strategic growth plans.
• Failure to remediate a material weakness in internal control over financial reporting, potentially impacting financial reporting accuracy.
• Risks associated with strategic alliances, including unforeseen integration obstacles, costs, and potential failure to achieve expected benefits.
• Inability to enter into collaboration agreements on favorable terms or at all, and dependence on collaborators' success.
• Potential involvement in litigation, regulatory or agency proceedings, investigations, and audits, leading to substantial costs and diversion of management attention.
• Challenges in protecting and defending intellectual property, including potential patent infringement suits and the risk of competitors developing similar technologies.
• Uncertainty in the timing of publicly announced milestones, which may differ significantly from expectations.
• Effectiveness of business development and marketing strategies in driving future growth and profitability.
• Intense competition in the biopharmaceutical industry from larger, better-financed competitors with broader service offerings.
• Market perception of smaller companies, potentially affecting share value and ability to raise funds.
• No guarantee of success in research and product development despite investment in scientific staff and R&D activities.
• Pressure on management and internal systems due to growth, requiring continuous improvement and expansion of employee base.
• Risks associated with the selection and integration of acquired businesses and technologies, including difficulties in achieving business success and potential undiscovered liabilities.
• Client contracts may be terminated with short notice (30 to 90 days), potentially leading to revenue decreases if major clients cancel.
• Reduction in demand for products and services due to decreased R&D expenditures by pharmaceutical and biotechnology companies.
• Reduction or delay in government funding of research and development, adversely affecting future revenue.
• Increased costs and disruptions to regular business operations as a public company in the United States.
• Revenue streams are contingent on meeting delivery and performance requirements in client contracts, limited by scientific process unpredictability and personnel shortages.
• Dependence on key personnel, with the loss of any key person or inability to attract new ones potentially having a material adverse effect.
• Inability to create sufficient brand awareness for expanded products and services.
• Potential conflicts of interest for directors, officers, or members of management.
• Industry trend of outsourcing non-clinical discovery stages of drug discovery may decrease, affecting growth rates.
• Risk of products, services, and expertise becoming obsolete or uneconomical due to rapid technological innovation and new approaches.
• Adverse effects from global economic turmoil and regional economic conditions, including restricted access to capital markets and impact on suppliers/clients.
• Dependence on a limited number of suppliers for animals and key biological/chemical materials, leading to supply chain risks.
• Inadequate insurance policies to fully protect against material judgments and expenses.
• Clients may restrict the use of scientific information, limiting the ability to improve efficiency of drug discovery services.
• Operational disruptions due to failure of laboratory facilities, including fires, earthquakes, and contaminations.
• Adverse impact from contaminations in animal populations, leading to inventory loss, clean-up costs, and reduced sales.
• Reliance on information technology systems and vulnerability to damaging cyber-attacks, including data breaches and compliance costs (GDPR, CCPA).
• Difficulties for United States investors to enforce civil liabilities against the company, its directors, and officers due to foreign incorporation.
• Status as a Foreign Private Issuer under U.S. securities laws, resulting in less detailed and frequent reporting compared to U.S. domestic issuers.
• Potential loss of Foreign Private Issuer status, leading to increased regulatory and compliance costs.
• Reliance on certain Canadian corporate governance practices that differ from Nasdaq standards, potentially affording less protection to shareholders.
• Failure to meet Nasdaq continued listing requirements, potentially resulting in delisting.
• Reliance on exemptions as an emerging growth company, which may make Common Shares less attractive to investors.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. Holders.
• Exposure to foreign exchange rate fluctuations.
• Dilution to existing shareholders from future sales or issuances of equity or debt securities.
• Volatility in the market price of securities due to various factors, including company announcements, competition, and general market conditions.
• Broad discretion in the use of proceeds from offerings, which may vary from planned use and not increase market value.
• No history of paying dividends and no intention to do so in the foreseeable future.
• Illiquidity of Common Shares, making it difficult for shareholders to sell significant quantities without price reduction.

Future Outlook

Operating costs are expected to increase in the near term as the company continues to build its AI-driven software development, LENS ai. This trend is anticipated to continue until subscription-based payments from future product sales, partnership fees, licensing fees, milestone payments, or royalty payments are sufficient to generate revenues to fund continuing operations.

Management Comments

• Management believes that the company's experience, innovation, technologies, scientific rigor, and focus on producing quality products provide a unique experience in one-stop service offerings, assisting in reducing time and inherent risk associated with conventional multi-vendor product development.
• Management believes that continued investment in retaining key scientific staff, as well as an ongoing commitment in R&D activities, will continue to be a cornerstone in the development of new services, processes, and competitive advantages.
• Management acknowledges that research and product development activities endeavor, but cannot assure, the production of new and innovative processes, procedures or innovative approaches to antibody production or new antibodies.
• Management believes that the company competes effectively with its competitors across factors such as full-service operating model, therapeutic expertise, global platform, and experienced and committed management team.
• Management believes the market acceptance of its products will continue as it organically grows its business, optimizes its laboratory, new sales and marketing capacity, and production process to support long-term growth.

Industry Context

The company operates in the rapidly growing biopharmaceutical discovery and development sector, specifically focusing on AI-driven therapeutic antibody research and contract research organization (CRO) services. The market for therapeutic antibodies is projected to reach U.S.$428 billion by 2029, growing at an 11.2% CAGR, driven by increasing R&D expenditures, innovative platforms, and demand for revolutionary therapies. The global immunoassay market is also expanding, expected to reach U.S.$46 billion by 2028. The company's strategic shift towards the therapeutic antibody market and integration of AI platforms like LENS ai and HYFT technology positions it within the forefront of industry innovation, aiming to reduce drug discovery time, cost, and risk. Its expansion in Europe and focus on end-to-end services align with the industry's outsourcing trend in non-clinical discovery stages.

Comparison to Industry Standards

• The company's gross profit margin of 55.3% in fiscal year 2025 is strong, especially compared to its 49.2% in fiscal year 2024, and is competitive within the CRO space, particularly with the BioStrand segment approaching 90% margins.
• The company's focus on AI-driven platforms like LENS ai and patented HYFT technology, and its ability to engineer in silico antibodies, positions it as an innovator compared to traditional CROs and aligns with the industry trend of leveraging advanced technologies for drug discovery.
• The company's partnerships with entities like OmniAb, BriaCell Therapeutics, Xyphos Biosciences (Astellas), InterSystems, Biotheus Inc., and RIBOPRO demonstrate its ability to engage with key players and integrate its technology into broader industry development pipelines, similar to how larger biopharmaceutical companies form strategic alliances.
• The company's recognition as an approved CRO for top-tier transgenic animal platforms producing human antibodies, and its optimization of services for various transgenic animal vendors, indicates a competitive advantage in a specialized niche compared to general CROs like Abveris Inc., Genovac GmbH, Antibody Solutions, Genscript Biotech Corp, and Curia Inc. (formerly Lake Pharma Inc.).
• Despite its innovative advancements, the company's continued net losses and reliance on capital raises for operations contrast with the profitability of established large pharmaceutical companies like AbbVie, Novartis, Roche, and Johnson & Johnson that dominate the therapeutic antibody market.

Management Changes

Corporate Governance

Legal Proceedings

• As of April 30, 2025, the company is not aware of any material legal proceedings to which it is a party or by which its property is subject, nor any such proceedings being contemplated.
• No penalties or sanctions imposed against the company by a court relating to securities legislation or by a securities regulatory authority, or any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor.
• No settlement agreements entered into before a court relating to securities legislation or with a securities regulatory authority.

Related Party Transactions

• The share purchase agreement for the acquisition of BioStrand includes contingent earnout payments based on 20% of BioStrand's EBITDA over a 7-year period, not to exceed €12.0 million.
• These earnout payments are contingent on the employment of two key employees and will be expensed in the period earned.
• As of April 30, 2025, no amount has been earned or paid on the company's contingent earnout related to the BioStrand acquisition.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing capital raises (ATM facility, convertible debentures) and potential future equity issuances. The increased net loss and going concern risk could negatively impact share price and investment value. However, regaining Nasdaq compliance and strategic advancements in AI and partnerships offer potential long-term value.
• **Employees**: The company's continued investment in R&D and expansion of lab facilities suggests job stability and growth opportunities, particularly in scientific and technical roles. However, the material weakness in internal controls and overall financial losses could pose risks to long-term stability if not addressed.
• **Customers (Clients)**: Benefit from the company's expanded service offerings, AI-driven platforms (LENS ai, HYFT), and specialized expertise in antibody discovery and development, potentially leading to faster and more efficient drug discovery processes. The acquisition of new instruments like Carterra's LSA platform enhances service capabilities.
• **Suppliers**: The company's dependence on a limited number of suppliers for key materials and animals exposes them to risks if supply is disrupted or terms become unfavorable.
• **Creditors**: The company's going concern risk and need for additional financing indicate a higher risk profile for creditors, although the recent full conversion of convertible debentures reduces immediate debt obligations.

Next Steps

• Continue to build out its AI-driven software development, LENS ai.
• Generate sufficient revenues from subscription-based payments, future product sales, partnership fees, licensing fees, milestone payments, or royalty payments to fund continuing operations.
• Remediate the identified material weakness in internal controls over financial reporting by implementing subject matter expert reviews and providing additional in-house training.
• Complete the lab expansion at 4464 Markham Street, Victoria, British Columbia, with an expected completion date prior to the end of early 2026.
• Discuss in good faith with Biotheus Inc. whether the evaluation results justify further collaboration, aiming for a Definitive Agreement within six months of evaluation completion.
• Continue to monitor developments and make appropriate changes to help attain compliance with evolving and complex data privacy and security regulations (e.g., GDPR, CCPA).

Key Dates

Recommendation

The company presents a mixed financial picture. While it achieved record revenue and significantly improved gross margins, driven by strong growth in its high-margin BioStrand AI segment, it continues to report substantial net losses and has explicitly stated it lacks sufficient cash for one year of operations, indicating ongoing liquidity challenges and going concern risk. The significant impairment charge on intangible assets also raises concerns about asset valuation and future profitability. However, the successful regaining of Nasdaq compliance removes an immediate delisting threat, and the company's strategic focus on AI-driven drug discovery and recent partnerships show potential for long-term value creation in a growing market. For existing investors, holding the stock might be warranted given the potential upside from its innovative AI platforms and strategic collaborations, assuming they are comfortable with the high risk associated with its current financial health and reliance on future capital raises. New investors should approach with extreme caution due to the significant financial risks.

Keywords

Antibody Discovery, Biotherapeutics, AI-driven Drug Discovery, Contract Research Organization, Biotechnology, Immuno-oncology, LENS ai, HYFT Technology, BioStrand, Nasdaq Compliance, SEC Filing, Financial Results, Liquidity, Capital Raise, Intellectual Property, Corporate Governance, Risk Management